Antonio Ferrari

At IQVIA, I lead three global Medical Scientific Services units across cardiovascular/renal/metabolic, early clinical development, and real-world evidence. I provide executive medical advice to pharma and biotech clients from clinical development plan design through regulatory submission.

I've built and scaled global medical functions, led Centres of Excellence, and provided oversight for medically complex programmes across a 200+ person organisation. My work spans Phase I-IV development, Medical Affairs, regulatory strategy, pharmacovigilance, RWE, GCP compliance, business development, and senior-team development.

Previously at EryDel and Chiesi, I led global clinical development, medical affairs, clinical safety, regulatory activities, and rare-disease programmes. I have worked directly with FDA, EMA, CFDA, TGA, DGI, MHRA, and AIFA, including securing a TQT exemption and worldwide approval for a Phase III Ataxia Telangiectasia study.

I'm a board-certified cardiologist and internal medicine specialist with extensive clinical practice, academic, and pharmaceutical leadership experience. I bring particular depth in cardiac safety, QT/TQT strategy, DSMB and safety-review governance, and building scientific teams that move complex assets forward.